Advertisement

Lung Cancer

Low Treatment Rates Underscore Need for New SCLC Therapies

Jul 15, 2022

Fewer than half of patients with small-cell lung cancer undergo treatment, and even fewer patients are treated with more than one line of therapy, according to study findings presented at the 2022 Ame...

MiR-144-3p inhibits the proliferation and metastasis of lung cancer A549 cells via targeting HGF.

May 16, 2022

MicroRNAs have been confirmed as vital regulators in gene expression, which could affect multiple cancer cell biological behaviors. This study aims to elucidate the molecular mechanism of miR-144-3p i...

The impact of segmentectomy versus lobectomy on pulmonary function in patients with non-small-cell lung cancer: a meta-analysis.

May 09, 2022

Segmentectomy has been reported as an alternative to lobectomy for small-sized NSCLC without detriment to survival. The long-term benefits of segmentectomy over lobectomy on pulmonary function have no...

A novel tRNA-derived fragment AS-tDR-007333 promotes the malignancy of NSCLC via the HSPB1/MED29 and ELK4/MED29 axes.

May 09, 2022

Transfer RNA-derived fragments (tRFs) are a new class of small non-coding RNAs. Recent studies suggest that tRFs participate in some pathological processes. However, the biological functions and mecha...

Identification of six novel prognostic gene signatures as potential biomarkers in Small Cell Lung Cancer.

May 02, 2022

As a subgroup of lung cancer, small cell lung cancer (SCLC) is characterized by a short tumor doubling time, high rates of early occurred distant cancer spread, and poor outcomes. Our study aimed to i...

#VisualAbstract: Neoadjuvant nivolumab plus chemotherapy increases event-free survival in resectable non-small-cell lung cancer

Apr 29, 2022

1. Neoadjuvant nivolumab plus chemotherapy led to a longer event-free survival and higher percentage of patients with a pathological complete response than chemotherapy alone. 2. Addition of ni...

Rebiopsy in advanced non-small cell lung cancer, clinical relevance and prognostic implications.

Apr 25, 2022

Rebiopsies of non-small cell lung cancers (NSCLC) are mainly performed to (i) cover the evolution of potentially amenable resistance mechanisms against a targeted therapy, and (ii) to identify new the...

Increased risk of cancer mortality by smoking-induced aryl hydrocarbon receptor repressor DNA hypomethylation in Japanese population: A long-term cohort study.

Apr 25, 2022

Smoking is well known to be a major risk factor for cancer, and to decrease the levels of aryl hydrocarbon receptor repressor (AHRR) DNA methylation. AHRR is a key regulator for AHR signaling, which i...

EpCAM-positive disseminated cancer cells in bone marrow impact on survival of early-stage NSCLC patients.

Apr 18, 2022

Detection of disseminated cancer cells (DCC) in bone marrow (BM) of patients with early-stage NSCLC has been associated with poor outcome. However, the phenotype, and hence relevant therapy targets, o...

Neoadjuvant chemoradiotherapy is superior to chemotherapy alone in surgically treated stage III/N2 non-small-cell lung cancer: a retrospective single-center cohort study.

Apr 11, 2022

There is lack of consensus whether neoadjuvant chemoradiotherapy (CHT/RT) is superior to neoadjuvant chemotherapy (CHT) alone in patients with potentially resectable stage III/N2 non-small-cell lung c...

In Silico and In Vitro Evaluations of Fluorophoric Thiazolo-[2,3-b]quinazolinones as Anti-cancer Agents Targeting EGFR-TKD.

Apr 04, 2022

Epidermal growth factor receptor tyrosine kinase domain (EGFR-TKD) plays a pivotal role in cellular signaling, growth, and metabolism. The EGFR-TKD is highly expressed in cancer cells and was endorsed...

Characteristics of Singapore lung cancer patients who miss out on lung cancer screening recommendations.

Apr 04, 2022

The National Lung Screening Trial (NLST) identified individuals at high risk for lung cancer and showed that serial low-dose helical computer tomographic scans (CT) were able to identify lung cancer a...

Aumolertinib: A Review in Non-Small Cell Lung Cancer.

Mar 21, 2022

Aumolertinib (formerly almonertinib; Ameile) is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (EGFR-TKI) that is selective for mutant EGFR over wild-type ...

Characterizing kinase intergenic-breakpoint rearrangements in a large-scale lung cancer population and real-world clinical outcomes.

Mar 21, 2022

Kinase gene fusions are strong driver mutations in neoplasia; however, kinase intergenic-breakpoint rearrangements (IGRs) confound the detection of such fusions and of targeted treatments. We aim to p...

Osimertinib-induced syndrome of inappropriate secretion of antidiuretic hormone in oncogene-addicted lung adenocarcinoma: A case report.

Mar 14, 2022

Asian patients with metastatic non-small cell lung cancer (NSCLC) have a higher prevalence of epidermal growth factor receptor (EGFR) mutations compared to Caucasians, 30-50% and 15%, respectively. Os...

Inhibiting nonhomologous end-joining repair would promote the antitumor activity of gemcitabine in nonsmall cell lung cancer cell lines.

Mar 14, 2022

Nonsmall cell lung cancer (NSCLC) is a major type of lung cancer. In current study, we aim to evaluate whether the combination of Ku70/80 heterodimer protein inhibitor STL127705 and gemcitabine would ...

Outcomes with durvalumab after chemoradiotherapy in stage IIIA-N2 non-small-cell lung cancer: an exploratory analysis from the PACIFIC trial.

Mar 07, 2022

The phase III PACIFIC trial (NCT02125461) established consolidation durvalumab as standard of care for patients with unresectable, stage III non-small-cell lung cancer (NSCLC) and no disease progressi...

Patient-Reported Outcome-Based Symptom Management Vs Usual Care

Feb 25, 2022

“Compared with usual care (UC), patient-reported outcome (PRO)-based symptom management can decrease symptom burden, improve QOL, cut ED visits, and extend survival time in patients undergoing syste...

Systematic review of fetal and placental metastases among pregnant patients with cancer.

Feb 21, 2022

Little is known about placental and fetal metastases among pregnant women with cancer. Therefore, we conducted a systematic review to identify the clinical and pathological characteristics, treatment ...

Deactivation of AKT/GSK-3β-mediated Wnt/β-catenin pathway by silencing of KIF26B weakens the malignant behaviors of non-small cell lung cancer.

Feb 21, 2022

Kinesin family member 26B (KIF26B) is reported differently expressed in multiple neoplasms and exerts a pivotal role in carcinogenesis. To date, the relationship between KIF26B and non-small cell lung...